Skip to main content
SpringerLink
Log in

Mononitrates

  • Chapter
Cardiovascular Drug Therapy

  • 39 Accesses

Abstract

The term “mononitrates” refers in general to the two metabolites of ISDN, namely, IS-5-MN and IS-2-MN. These metabolites are formed in the liver.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nyberg G, Blychert L-O, Jonsson UE (1985) Pharmacokinetics of isosorbide-5-mononitrate in a controlled-release (Durules) formulation. Br J Clin Pharmacol 20: 541p

    Google Scholar 

  2. Krepp HP (1985) Langzeitehandlung der koronaren Herzerkrankung mit elantan long. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich, pp 176–183

    Google Scholar 

  3. Ohlmeier H, Mertens HM, Mannebach H, Gleichmann U (1985) Tolerance and rebound phenomena in nitrate therapy. In: Cohn JH, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 107–123

    Chapter  Google Scholar 

  4. Eggeling T, Osterspey A, Geppert R, Jansen W (1985) Antianginöse Wirksamkeit von retardiertem Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich pp 76–87

    Google Scholar 

  5. Akhras G, Jackson C (1986) Isosorbide-5-mononitrate as monotherapy in patients with chronic stable angina (Abstract). J Am Coll Cardiol 7–230A

    Google Scholar 

  6. Bidoggia JH, Casar JE, Hirschon AJ, Campo A, Nordaby R (1985) Beneficial effects of isosorbide-5-mononitrate on exercise performance in patients with chronic stable angina pectoris. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 201–214

    Chapter  Google Scholar 

  7. Uusitalo A, Keyriläinen O, Härkönen R, Penti R et al. (1988) Antianginal efficacy of a controlled release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic β-blockade. Acta Med Scand 223: 219–225

    Article  PubMed  CAS  Google Scholar 

  8. Nyberg G, Carlens P, Lindström E, Lundman T et al. (1986) The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study. Eur Heart J 7: 835–842

    PubMed  CAS  Google Scholar 

  9. Svendsen JH, Aldershvile J, Abildgaard U, Amtorp O (1987) Efficacy of isosorbide-5-mononitrate in angina pectoris patients. An abstract presented at the XI Scandinavian congress of cardiology, Kuopio, Finland, Aug 1987

    Google Scholar 

  10. Svensen JH, Aldershvile J, Amtorp O (1986) Absence of nitrate crosstolerance during slow-release isosorbide-5-mononitrate (5 MN) treatment. Acta Pharmacol Toxicol [Suppl V]: 179

    Google Scholar 

  11. Schiavoni G, Montenero AS, Mazzari M, Biasucci LM, Manzoli U (1985) The efficacy of IS-5-MN in patients with ischemic heart disease: a pilot study. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer Berlin Heidelberg New York, pp 230–234

    Chapter  Google Scholar 

  12. Myberg G, Jonsson U (1986) Can tolerance development with 5-isosorbide mononitrate be avoided with a once-daily controlledrelease formulation? Acta Pharmacol Toxicol [Suppl V]: 148

    Google Scholar 

  13. Meffert M, Paeckelmann I-M (1987) Experience of long-term treatment and different dosage regimens of isosorbide-5-mononitrate. Drugs 33[Suppl 4]: 104–110

    Article  PubMed  Google Scholar 

  14. Uusitalo A (1987) Long-term efficacy of a controlled release formulation of isosorbide-5-mononitrate (Imdur) in angina patients receiving β-blockers. Drugs 33[Suppl 4]: 111–117

    Article  PubMed  Google Scholar 

  15. Rehnqvist N, Olsson G, Engvall J et al. (1987) Abrupt withdrawal of isosorbide-5-mononitrate (Imdur) after long-term treatment in stable angina pectoris. Drugs 33[Suppl 4]: 118–121

    Article  PubMed  Google Scholar 

  16. Rennhak U, Riebesel T, Biamino G (1985) A double-blind cross-over study on the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow-release in coronary artery disease. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York, pp 147–153

    Chapter  Google Scholar 

  17. Mentzel M (1984) Ein-Jahresstudie mit Elantan bei Patienten mit koronarer Herzerkrankung — Wirksamkeit und Verträglichkeit im Rahmen einer Langzeitbehandlung. In: Hochrein H, Tauchert M, Schrey A, Weiss M (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich pp 98–111

    Google Scholar 

  18. Heepe W (1984) Langzeittherapie der Patienten mit koronarer Herzkrankheit mit IS-5-MN retard. In: Hochrein H, Tauchert M, Schrey A, Weiss M (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich, pp 172–229

    Google Scholar 

  19. Tauchert M, Jansen W, Osterspey A, Fuchs M, Hombach V, Hilger HH (1983) Dose dependence of tolerance during treatment with mononitrates. Z Kardiol 72[Suppl 3]: 218–228

    PubMed  Google Scholar 

  20. Kenedi P (1985) Intraindividuelle Dosiswirkungsbeziehung von elantan long. In: Borchard U, Rafflenbeul W, Schrey A (eds) Mononitrat. Universitätsdruckerei und Wolf, Munich pp 108–115

    Google Scholar 

  21. Thadani U, Hamilton SF, Olson E et al. (1987) Duration of effects and tolerance of slow-release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol 59: 756–762

    Article  PubMed  CAS  Google Scholar 

  22. Müller G, Überbacher HJ, Glocke M (1983) Koronartherapeutische Wirksamkeit von niedrig dosiertem Isosorbide-5-Mononitrate im Vergleich zur Kombination von IS-5-MN und Metipranolol und Placebo. Med Welt 34: 321–327

    PubMed  Google Scholar 

  23. Koch G, Fransson L, Karlegärd L, Sauer W, Übberbacher HJ (1985) Double-blind comparison of the effects of nifedipine and isosorbide-5-mononitrate on the circulatory response to exercise, exercise tolerance, and ST-segment depression in patients with ischemic heart disease. In: Cohn JH, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg, New York pp 245–253

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 9, Kehilat Sofia St., Tel Aviv, 69018, Israel

    Adam Schneeweiss MD (Chairman)

Authors
  1. Adam Schneeweiss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schneeweiss, A. (1990). Mononitrates. In: Cardiovascular Drug Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74617-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74617-8_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50962-2

  • Online ISBN: 978-3-642-74617-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation